Vicore Pharma Q3 2026: Strong Cash Position, Rising R&D Losses, and Buloxibutid’s IPF Road‑Map
Vicore Pharma’s Q3 2026 report shows solid cash, rising R&D spend for buloxibutid, and a clear plan to tackle the $15B IPF market with a potentially differentiated therapy.
3 minutes to read










